UY35774A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
UY35774A
UY35774A UY0001035774A UY35774A UY35774A UY 35774 A UY35774 A UY 35774A UY 0001035774 A UY0001035774 A UY 0001035774A UY 35774 A UY35774 A UY 35774A UY 35774 A UY35774 A UY 35774A
Authority
UY
Uruguay
Prior art keywords
compound
salt
heterocyclic compound
medicament
sstr5
Prior art date
Application number
UY0001035774A
Other languages
English (en)
Inventor
Yamasaki Takeshi
Yamashita Tohrutohru
Nishikawa Yoichi
Kina Asato
hirose Hideki
Kasai Shizuo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35774A publication Critical patent/UY35774A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. De forma específica, se proporciona un compuesto representado por la fórmula que aparece a continuación:en donde cada símbolo es como se lo define en la presente,o una sal de él, un medicamento que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus.
UY0001035774A 2013-10-07 2014-10-06 Compuesto heterocíclico UY35774A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
UY35774A true UY35774A (es) 2015-05-29

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035774A UY35774A (es) 2013-10-07 2014-10-06 Compuesto heterocíclico

Country Status (23)

Country Link
US (2) US9353108B2 (es)
EP (1) EP3055309B1 (es)
JP (1) JP6411520B2 (es)
CN (1) CN105612158B (es)
AR (1) AR097932A1 (es)
BR (1) BR112016007620B1 (es)
CA (1) CA2926544C (es)
CY (1) CY1121163T1 (es)
DK (1) DK3055309T3 (es)
ES (1) ES2687102T3 (es)
HR (1) HRP20181372T1 (es)
HU (1) HUE039386T2 (es)
JO (1) JO3442B1 (es)
LT (1) LT3055309T (es)
PL (1) PL3055309T3 (es)
PT (1) PT3055309T (es)
RS (1) RS57743B1 (es)
RU (1) RU2671958C2 (es)
SI (1) SI3055309T1 (es)
TR (1) TR201810506T4 (es)
TW (1) TWI648276B (es)
UY (1) UY35774A (es)
WO (1) WO2015052910A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605000B2 (en) * 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
EP3227282B1 (en) * 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
TW202207929A (zh) * 2020-05-13 2022-03-01 日商思可海雅藥品股份有限公司 膽道系疾病的診斷輔助、預防或治療劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN116354961A (zh) * 2021-12-27 2023-06-30 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
US7071207B2 (en) 2001-09-24 2006-07-04 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
MXPA04002035A (es) * 2001-09-26 2004-06-07 Bayer Pharmaceuticals Corp Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
AU2004220225B2 (en) 2003-03-14 2010-06-17 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
JP2007513082A (ja) 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
AU2006277231A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP2010500391A (ja) 2006-08-15 2010-01-07 エフ．ホフマン−ラ ロシュ アーゲー フェニル、ピリジン及びキノリン誘導体
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AU2010245889A1 (en) 2009-05-07 2011-11-03 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
PT3063139T (pt) 2013-10-29 2019-02-22 Takeda Pharmaceuticals Co Composto heterocíclico

Also Published As

Publication number Publication date
EP3055309B1 (en) 2018-06-13
RU2016117732A (ru) 2017-11-15
US9353108B2 (en) 2016-05-31
EP3055309A1 (en) 2016-08-17
TWI648276B (zh) 2019-01-21
BR112016007620A2 (pt) 2017-08-01
TR201810506T4 (tr) 2018-08-27
JO3442B1 (ar) 2019-10-20
WO2015052910A1 (en) 2015-04-16
BR112016007620B1 (pt) 2020-05-26
PT3055309T (pt) 2018-10-01
CA2926544C (en) 2021-07-06
US20160237087A1 (en) 2016-08-18
AR097932A1 (es) 2016-04-20
SI3055309T1 (sl) 2018-10-30
JP6411520B2 (ja) 2018-10-24
LT3055309T (lt) 2018-08-27
JP2016531950A (ja) 2016-10-13
CA2926544A1 (en) 2015-04-16
HUE039386T2 (hu) 2018-12-28
DK3055309T3 (en) 2018-08-27
HRP20181372T1 (hr) 2018-10-19
TW201536784A (zh) 2015-10-01
CN105612158B (zh) 2017-06-30
RS57743B1 (sr) 2018-12-31
US9751878B2 (en) 2017-09-05
PL3055309T3 (pl) 2018-10-31
CN105612158A (zh) 2016-05-25
CY1121163T1 (el) 2020-05-29
ES2687102T3 (es) 2018-10-23
US20150099777A1 (en) 2015-04-09
RU2671958C2 (ru) 2018-11-08

Similar Documents

Publication Publication Date Title
DOP2016000206A (es) Compuesto heterocíclico fusionado
UY35995A (es) Compuesto heterocíclico
UY35774A (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
CR20150205S (es) Almohada de viaje
CL2015003483A1 (es) Composiciones que comprenden tintes fotocrómicos para el tratamiento de superficies.
DK3174868T3 (da) Forbindelser, der er aktive mod bromodomæner
CR20120448A (es) Compuesto heterocíclico
DOP2015000140A (es) Compuesto heterocíclico
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
CO2017003699A2 (es) Compuesto heterocíclico
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
UY35650A (es) Compuesto heterocíclico
CL2014002397A1 (es) Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp.
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
UY34752A (es) Agentes para el control de la chinche del eucalipto
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
CR20150533A (es) Compuesto peptídico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211215